Comments
Drug firm Lupin on Tuesday said its Japanese arm and YL Biologics have submitted a new drug application with the Japanese health regulator PMDA for marketing authorisation of a biosimilar of Etanercept used for treating rheumatoid arthritis at an affordable price.
The application for Etanercept biosimilar is a significant milestone for Lupin as the company is building a pipeline of biosimilars. Shareholders of the company will closely monitor the development.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.